Compare BGIN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGIN | KPTI |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | Singapore | United States |
| Employees | 88 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.6M | 194.8M |
| IPO Year | N/A | 2013 |
| Metric | BGIN | KPTI |
|---|---|---|
| Price | $1.70 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 7.8K | ★ 1.9M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.66 | $1.80 |
| 52 Week High | $5.19 | $10.99 |
| Indicator | BGIN | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 15.20 |
| Support Level | $1.71 | N/A |
| Resistance Level | $2.08 | $7.01 |
| Average True Range (ATR) | 0.12 | 0.69 |
| MACD | 0.01 | -0.64 |
| Stochastic Oscillator | 16.77 | 1.96 |
BGIN Blockchain Ltd is a digital asset technology company engaged in cryptocurrency mining technologies, self-mining operations, and the design and sale of ASIC mining machines. The company develops proprietary mining hardware under its ICERIVER brand and provides mining infrastructure and hosting solutions. It operates through two reportable segments: cryptocurrency mining and sale of mining machines. The company focuses on cryptocurrencies such as Bitcoin, Dogecoin, KAS, ALPH, and RXD. Geographically, it derives revenue from Hong Kong, China, Vietnam, the United States, Singapore, and other markets.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).